NURIX THERAPEUTICS INC. 2024-2025 Proxy Voting Records

Description as filed by funds: Election of Directors: Judith A. Reinsdorf

NURIX THERAPEUTICS INC.’s own tally for this item (“Elect Director: Judith A. Reinsdorf”): 43,571,416 for, 17,651,464 withheld, per its Form 8-K filed May 19, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors Each of the three nominees for director was elected to serve until the Company's 2028 annual meeting of stockholders and until his or her successor has been elected and qualified, or until his or her earlier resignation or removal.”
Support: 71% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 63 asset managers below reported 17,785,352 for, 9,986,181 withheld, 41,376 abstained.

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

Description as filed by funds: Election of Directors: Edward C. Saltzman

NURIX THERAPEUTICS INC.’s own tally for this item (“Elect Director: Edward C. Saltzman”): 50,302,518 for, 10,920,362 withheld, per its Form 8-K filed May 19, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors Each of the three nominees for director was elected to serve until the Company's 2028 annual meeting of stockholders and until his or her successor has been elected and qualified, or until his or her earlier resignation or removal.”
Support: 82% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 62 asset managers below reported 18,438,796 for, 9,321,346 withheld, 10,767 abstained.

Showing the 25 largest of 62 asset managers. See all 62 in the interactive database.

Description as filed by funds: Election of Directors: Roy D. Baynes

NURIX THERAPEUTICS INC.’s own tally for this item (“Elect Director: Roy D. Baynes”): 60,821,712 for, 401,168 withheld, per its Form 8-K filed May 19, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors Each of the three nominees for director was elected to serve until the Company's 2028 annual meeting of stockholders and until his or her successor has been elected and qualified, or until his or her earlier resignation or removal.”
Support: 99.3% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 62 asset managers below reported 27,534,237 for, 225,905 withheld, 10,767 abstained.

Showing the 25 largest of 62 asset managers. See all 62 in the interactive database.

Description as filed by funds: To approve, a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement.

NURIX THERAPEUTICS INC.’s own tally for this item (“3. Approval, on a Non-binding Advisory Basis, of the Compensation of the Company's Named Executive Officers”): 49,788,975 for, 11,341,365 against — passed, per its Form 8-K filed May 19, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3. Approval, on a Non-binding Advisory Basis, of the Compensation of the Company's Named Executive Officers”
Support: 81% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 63 managers: 18,731,225 for, 9,033,690 against, 47,994 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 155 managers: 38,661,769 for, 11,034,754 against, 18,947 withheld, 3,824 abstained, 46 not voted. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending November 30, 2025.

NURIX THERAPEUTICS INC.’s own tally for this item (“2. Ratification of Appointment of Independent Registered Public Accounting Firm”): 64,950,599 for, 85,040 against — passed, per its Form 8-K filed May 19, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending November 30, 2025.”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 63 asset managers below reported 27,806,902 for, 13 against, 5,994 abstained.

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.